35214 Federal Register / Vol. 87, No. 111 / Thursday, June 9, 2022 / Notices 

The Acquisition would likely 

substantially lessen competition in each 

local market. In North Augusta, Buckeye 

and Magellan are two of only three firms 

that offer terminaling services for LPPs 

and for gasoline. The markets are highly 

concentrated with the significant 

increase in concentration giving rise to 

a presumption of enhanced market 

power post-Acquisition. In Spartanburg, 

as measured by LPP capacity, Buckeye 

owns the largest terminal and Magellan 

owns the second largest. The 

Acquisition would result in highly 

concentrated markets for LPP and 

gasoline terminaling services with a 

change in concentration giving rise to a 

presumption of enhanced market power. 

In Montgomery, the Acquisition would 

reduce the number of terminal service 

operators from six to five, resulting in a 

moderately concentrated market postAcquisition, and would also reduce the 

number of gasoline terminal operators 

from five to four, resulting in a highly 

concentrated market post-Acquisition. 

Moreover, Buckeye and Magellan are 

two of few independent gasoline 

terminal operators in Montgomery, who 

have little or no refining or marketing 

activities that can be supported by their 

terminal operations. The Acquisition 

would leave as few as two independent 

gasoline terminal operators in 

Montgomery and limit options for third 

parties to access independent 

terminaling services providers in that 

market. 

Entry into each relevant market would 

not be timely, likely, or sufficient to 

deter or counteract the anticompetitive 

effects arising from the Acquisition. 

Barriers to entry are significant and 

include high sunk costs associated with 

the construction of a new terminal and 

the time required to design, build, and 

permit a new facility. 

V. The Proposed Order and the Order 

To Maintain Assets 

The proposed Order and the Order to 

Maintain Assets would remedy the 

Acquisition’s likely anticompetitive 

effects alleged in the Commission’s 

Complaint by requiring Buckeye to 

divest the Magellan terminals and all 

associated assets (the ‘‘Terminal 

Divestiture Assets’’) in North Augusta, 

Spartanburg, and Montgomery to U.S. 

Venture. The proposed Order ensures 

that U.S. Venture or any other acquirer 

can operate the terminals in a manner 

equivalent in all material respects to the 

manner in which Magellan operated 

those businesses prior to the 

Acquisition. 

U.S. Venture is a privately held 

company that was founded in 1951 and 

currently has a number of divisions, 

including U.S. Oil. U.S. Oil will be 

responsible for operating the divested 

terminals. U.S. Oil owns and operates 

26 terminals in Iowa, Michigan, Indiana, 

Wisconsin, and Texas serving retail 

customers at 11 locations. U.S. Oil does 

not have any refined products terminals 

in the southeastern United States. 

The proposed Order requires Buckeye 

to divest the Terminal Divestiture 

Assets no later than 10 days after 

Buckeye and Magellan consummate the 

Acquisition. 

The proposed Order and the Order to 

Maintain Assets contain additional 

provisions designed to ensure the 

effectiveness of the relief. Both the 

proposed Order and the Order to 

Maintain Assets require Respondents to 

maintain the Terminal Divestiture 

Assets’ full economic viability, 

marketability, and competitiveness until 

the divestitures are completed and to 

help facilitate the transfer of the 

Terminal Divestiture Assets to U.S. 

Venture. 

In addition to requiring divestiture of 

the Terminal Divestiture Assets, the 

proposed Order requires Buckeye to 

seek prior approval from the 

Commission before acquiring any LPP 

terminal (including the divested 

terminals) within a 60-mile radius of the 

Terminal Divestiture Assets because an 

acquisition in close proximity to 

divested assets likely would raise the 

same competitive concerns as the 

Acquisition and may fall below the 

Hart-Scott-Rodino Act premerger 

notification thresholds. The proposed 

Order further requires U.S. Venture to 

obtain prior approval from the 

Commission for a period of three years 

before transferring any of the divested 

assets to any buyer, and for a period of 

seven additional years to any buyer with 

an interest in any LLP terminal in any 

of the three relevant geographic markets. 

Finally, the proposed Order appoints 

The Claro Group as an independent 

third-party monitor to oversee the 

Respondents’ compliance with the 

requirements of the proposed Order. 

The Claro Group has previous 

experience serving as a monitor for the 

Commission in matters relating to 

natural gas pipelines and retail gasoline 

outlets. 

The purpose of this analysis is to 

facilitate public comment on the 

proposed Order, and the Commission 

does not intend this analysis to 

constitute an official interpretation of 

the proposed Order or to modify its 

terms in any way. 

By direction of the Commission. 

April J. Tabor, 

Secretary. 

[FR Doc. 2022–12430 Filed 6–8–22; 8:45 am] 

BILLING CODE 6750–01–P 

GOVERNMENT ACCOUNTABILITY 

OFFICE 

Request for Nominations for the 

Physician-Focused Payment Model 

Technical Advisory Committee 

AGENCY: U.S. Government 

Accountability Office (GAO). 

ACTION: Request for letters of 

nomination and resumes. 

SUMMARY: The Medicare Access and 

CHIP Reauthorization Act of 2015 

established the Physician-Focused 

Payment Model Technical Advisory 

Committee (PTAC) to provide comments 

and recommendations to the Secretary 

of Health and Human Services on 

physician payment models and gave the 

Comptroller General responsibility for 

appointing its members. GAO is now 

accepting nominations of individuals 

for this committee. 

DATES: Letters of nomination and 

resumes should be submitted no later 

than July 11, 2022, to ensure adequate 

opportunity for review and 

consideration of nominees prior to 

appointment. Appointments will be 

made in October 2022. 

ADDRESSES: Submit letters of 

nomination and resumes to 

PTACcommittee@gao.gov. 

FOR FURTHER INFORMATION CONTACT: Greg 

Giusto at (202) 512–8268 or giustog@

gao.gov if you do not receive an 

acknowledgement within a week of 

submission or you need additional 

information. For general information, 

contact GAO’s Office of Public Affairs at 

(202) 512–4800. 

Authority: Sec. 101(e), Public Law 

114–10, 129 Stat. 87, 115 (2015). 

Gene L. Dodaro, 

Comptroller General of the United States. 

[FR Doc. 2022–12447 Filed 6–8–22; 8:45 am] 

BILLING CODE 1610–02–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Meeting 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Notice. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 111 / Thursday, June 9, 2022 / Notices 35215 

SUMMARY: The Agency for Healthcare 

Research and Quality (AHRQ) 

announces a Special Emphasis Panel 

(SEP) meeting on ‘‘Diagnostic Centers of 

Excellence: Partnerships to Improve 

Diagnostic Safety and Quality (R18).’’ 

This SEP meeting will be closed to the 

public. 

DATES: July 14–15, 2022 

ADDRESSES: Agency for Healthcare 

Research and Quality, (Video Assisted 

Review), 5600 Fishers Lane, Rockville, 

Maryland 20857. 

FOR FURTHER INFORMATION CONTACT: 

Jenny Griffith, Committee Management 

Officer, Office of Extramural Research, 

Education and Priority Populations, 

Agency for Healthcare Research and 

Quality, (AHRQ), 5600 Fishers Lane, 

Rockville, Maryland 20857. Telephone: 

(301) 427–1557. 

SUPPLEMENTARY INFORMATION: A Special 

Emphasis Panel is a group of experts in 

fields related to health care research 

who are invited by AHRQ, and agree to 

be available, to conduct on an as needed 

basis, scientific reviews of applications 

for AHRQ support. Individual members 

of the Panel do not attend regularly 

scheduled meetings and do not serve for 

fixed terms or a long period of time. 

Rather, they are asked to participate in 

particular review meetings which 

require their type of expertise. 

The SEP meeting referenced above 

will be closed to the public in 

accordance with the provisions set forth 

in 5 U.S.C. app. 2, section 10(d), 5 

U.S.C. 552b(c)(4), and 5 U.S.C. 

552b(c)(6). Grant applications for 

‘‘Diagnostic Centers of Excellence: 

Partnerships to Improve Diagnostic 

Safety and Quality (R18)’’ are to be 

reviewed and discussed at this meeting. 

The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Agenda items for this meeting are 

subject to change as priorities dictate. 

Dated: June 6, 2022. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2022–12433 Filed 6–8–22; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2022–0079] 

Advisory Committee on Immunization 

Practices (ACIP) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), located within the 

Department of Health and Human 

Services (HHS), announces the 

following meeting of the Advisory 

Committee on Immunization Practices 

(ACIP). This meeting is open to the 

public. Time will be available for public 

comment. 

DATES: The meeting will be held on June 

17, 2022, from 10:00 a.m. to 3:30 p.m., 

EDT, and June 18, 2022, from 10:00 a.m. 

to 4:00 p.m., EDT (times subject to 

change). The meeting will be webcast 

live via the World Wide Web. Written 

comments must be received on or before 

June 21, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0079, by either of the following 

methods: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

Mailstop H24–8, Atlanta, Georgia 

30329–4027, Attn: June 17–18, 2022, 

ACIP Meeting. 

Instructions: All submissions received 

must include the Agency name and 

Docket Number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, ACIP Committee 

Management Specialist, Centers for 

Disease Control and Prevention, 

National Center for Immunization and 

Respiratory Diseases, 1600 Clifton Road 

NE, Mailstop H24–8, Atlanta, Georgia 

30329–4027; Telephone: (404) 639– 

8367; Email: ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with 41 CFR 102–3.150(b), 

less than 15 calendar days’ notice is 

being given for this meeting due to the 

exceptional circumstances of the 

COVID–19 pandemic and rapidly 

evolving COVID–19 vaccine 

development and regulatory processes. 

The Secretary of Health and Human 

Services has determined that COVID–19 

is a Public Health Emergency. A notice 

of this ACIP meeting has also been 

posted on CDC’s ACIP website at: 

https://www.cdc.gov/vaccines/acip/ 

index.html. In addition, CDC has sent 

notice of this ACIP meeting by email to 

those who subscribe to receive email 

updates about ACIP. 

Purpose: The committee is charged 

with advising the Director, CDC, on the 

use of immunizing agents. In addition, 

under 42 U.S.C. 1396s, the committee is 

mandated to establish and periodically 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children program, along 

with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under provisions of the Affordable Care 

Act, section 2713 of the Public Health 

Service Act, immunization 

recommendations of the ACIP that have 

been approved by the CDC Director and 

appear on CDC immunization schedules 

must be covered by applicable health 

plans. 

Matters to be Considered: The agenda 

will include discussions on the use of 

COVID–19 pediatric vaccines. A 

recommendation vote(s) is scheduled. 

Agenda items are subject to change as 

priorities dictate. For more information 

on the meeting agenda, visit https://

www.cdc.gov/vaccines/acip/meetings/ 

index.html. The meeting will be webcast 

live via the World Wide Web; for more 

information on ACIP, visit the ACIP 

website: https://www.cdc.gov/vaccines/ 

acip/index.html. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 


lotter on DSK11XQN23PROD with NOTICES1